Jazz Pharmaceuticals (JAZZ) PT Raised to $190 at Cowen, Positive on GW Deal

February 3, 2021 12:02 PM EST
Get Alerts JAZZ Hot Sheet
Price: $167.16 -1.03%

Rating Summary:
    32 Buy, 3 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 18 | Down: 20 | New: 68
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Cowen analyst Ken Cacciatore raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $190.00 (from $180.00) while maintaining an Outperform rating on GW deal.

The analyst commented, "Jazz is acquiring GW which further diversifies the revenue/pipeline, bringing Epidiolex in epilepsy and Nabiximols for MS spasticity in Phase III. Put simply, we like this transaction as we believe in Jazz's ability to analyze difficult IP situations, which is key to valuing Epidiolex's durability. And with likely success of Nabiximols (that is not factored by the Street), this deal works. Add."

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Cowen & Co